Dose Dependent Effects of Intravitreal Triamcinolone Acetonide on Diffuse Diabetic Macular Edema
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the effect of different doses of intravitreal triamcinolone acetonide on diffuse diabetic macular edema. Methods: In a retrospective study, 44 eyes with diffuse diabetic macular edema were treated with an intravitreal injection of 4 ㎎ (n=12 eyes), 8 ㎎ (n=17) or 25 ㎎ (n=15) of triamcinolone acetonide (TA). Optical coherence tomography, best-corrected logMAR visual acuity and Goldmann tonometry were performed at baseline, 1 week, and 1, 3, 6, 9 and 12 months after treatment. Mean follow-up was 9.8 months (standard deviation=2.3) with a range of 5-12 months. Results: The duration of intravitreal TA effects on macular thickness and visual acuity increased with increasing dosage. An observed increase in intraocular pressure induced by TA was not significantly associated with dosage. Conclusions: In patients with diffuse diabetic macular edema who receive intravitreal TA, effects may last longer after a dosage of 25 ㎎, than after lower doses of 8 ㎎ or 4 ㎎.
Abstract
Purpose: To evaluate the effect of different doses of intravitreal triamcinolone acetonide on diffuse diabetic macular edema. Methods: In a retrospective study, 44 eyes with diffuse diabetic macular edema were treated with an intravitreal injection of 4 ㎎ (n=12 eyes), 8 ㎎ (n=17) or 25 ㎎ (n=15) of triamcinolone acetonide (TA). Optical coherence tomography, best-corrected logMAR visual acuity and Goldmann tonometry were performed at baseline, 1 week, and 1, 3, 6, 9 and 12 months after treatment. Mean follow-up was 9.8 months (standard deviation=2.3) with a range of 5-12 months. Results: The duration of intravitreal TA effects on macular thickness and visual acuity increased with increasing dosage. An observed increase in intraocular pressure induced by TA was not significantly associated with dosage. Conclusions: In patients with diffuse diabetic macular edema who receive intravitreal TA, effects may last longer after a dosage of 25 ㎎, than after lower doses of 8 ㎎ or 4 ㎎.
참고문헌 (21)
- Klein R, "Visual impairment in diabetes", Ophthalmology, 91, pp.1~9 (1984)
- Photocoagulation for diabetic macular edema, "Early Treatment Diabetic Retinopathy Study report number 1 Early Treatment Diabetic Retinopathy Study Research Group", Arch Ophthalmol, 103, pp.1796~1806 (1985)
- McDonald HR, "Grid photocoagulation for diffuse macular edema", Retina, 5, pp.65~72 (1985)
- Jonas JB, "Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy", Am J Ophthalmol, 131, pp.468~471 (2001)
- Jonas JB, "Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema", Am J Ophthalmol, 132, pp.425~427 (2001)
- Wilson CA, "Treatment with intravitreal steroid reduces bloodretinal barrier breakdown due to retinal photocoagulation", Arch Ophthalmol, 110, pp.1155~1159 (1992)
- Spandau UH, "Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema", Br J Ophthalmol, 89, pp.999~1003 (2005)
- Massin P, "Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial", Ophthalmology, 111, pp.218~224 (2004)
- Al-Haddad CE, "Intravitreal triamcinolone acetonide for the management of diabetic papillopathy", Am J Ophthalmol, 137, pp.1151~1153 (2004)
- Jonas JB, "Intravitreal injection of triamcinolone for diffuse diabetic macular edema", Arch Ophthalmol, 121, pp.57~61 (2003)
- Martidis A, "Intravitreal triamcinolone for refractory diabetic macular edema", Ophthalmology, 109, pp.920~927 (2002)
- Jonas JB, "Duration of the effect of intravitreal triamcinolone acetonide as treatment of diffuse diabetic macular edema", Am J Ophthalmol, 138, pp.158~160 (2004)
- Wingate RJ, "Intravitreal triamcinolone and elevated intraocular pressure", Aust N Z J Ophthalmol, 27, pp.431~432 (1999)
- Jonas JB, "Intraocular pressure after intravitreal injection of triamcinolone acetonide", Br J Ophthalmol, 87, pp.24~27 (2003)
- Jonas JB, "Secondary chronic open- angle glaucoma after intravitreal triamcinolone acetonide", Arch Ophthalmol, 121, pp.729~730 (2003)
- Smithen LM, "Intravitreal triamcinolone acetonide and intraocular pressure", Am J Ophthalmol, 138, pp.740~743 (2004)
- Benz MS, "Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone", Arch Ophthalmol, 121, pp.271~273 (2003)
- Jonas JB, "Endophthalmitis after intravitreal injection of triamcinolone acetonide", Arch Ophthalmol, 121, pp.1663~1664 (2003)
- Moshfeghi DM, "Acute endophthalmitis following intravitreal triamcinolone acetonide injection", Am J Ophthalmol, 136, pp.791~796 (2003)
- Nelson ML, "Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection", Retina, 23, pp.686~691 (2003)
- Parke DW, "Intravitreal triamcinolone and endophthalmitis", Am J Ophthalmol, 136, pp.918~919 (2003)